A Toad Less Traveled: Should 5-MeO-DMT Have a Role in Treating Depression?
Psychedelic Medicine April 14, 2025 DOI: 10.1089/psymed.2024.0049 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Topics | 5-MeO-DMT Depression DMT |
| Key points | Argues that 5-MeO-DMT's unusual properties may offer cost-effectiveness and practicality for healthcare providers, but those same features could limit its success as a mainstream antidepressant, and recommends measures for future clinical trials. |
Abstract
As the therapeutic potential of psychedelics is becoming more established, a wider range of compounds are beginning to be investigated for their antidepressant properties. 5-Methoxy- N , N -dimethyltryptamine (5-MeO-DMT) is one such example; its unusual properties may make it a more cost-effective and practical choice for health care providers. However, the same distinctive features may mean that its potential for success as a mainstream treatment option for depression is limited. There is very little existing literature around 5-MeO-DMT, and it is scarcely used even within the psychedelics community. This may mean that it is even more difficult to recruit a diverse range of subjects, which is already an issue for clinical trials involving other psychedelics. The aim of this article is to discuss the hypothetical pros and cons of 5-MeO-DMT as an antidepressant and to make recommendations for measures to be taken in any future clinical trials investigating 5-MeO-DMT.